Sarcoma  >>  temozolomide  >>  Phase 3
Welcome,         Profile    Billing    Logout  

11 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
temozolomide / Generic mfg.
NCT00304031: Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

Completed
3
1173
Canada, US
Concurrent temozolomide, Concurrent radiation therapy, 100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle, 75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle
Radiation Therapy Oncology Group, National Cancer Institute (NCI), European Organisation for Research and Treatment of Cancer - EORTC, NRG Oncology
Brain and Central Nervous System Tumors
02/11
12/16
NCT00884741: Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma

Checkmark Glioblastoma
Feb 2014 - Feb 2014: Glioblastoma
Checkmark ASCO-2013
Jun 2013 - Jun 2013: ASCO-2013
Checkmark RTOG 0825 study for glioblastoma
More
Completed
3
637
Canada, US, RoW
3-Dimensional Conformal Radiation Therapy, 3-dimensional radiation therapy, 3D CONFORMAL RADIATION THERAPY, 3D CRT, 3D-CRT, Conformal Therapy, Radiation Conformal Therapy, Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar FKB238, BEVACIZUMAB, LICENSE HOLDER UNSPECIFIED, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, Intensity-Modulated Radiation Therapy, IMRT, Intensity Modulated RT, Intensity-Modulated Radiotherapy, Laboratory Biomarker Analysis, Placebo, placebo therapy, PLCB, sham therapy, Quality-of-Life Assessment, Quality of Life Assessment, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac
National Cancer Institute (NCI), Radiation Therapy Oncology Group, NRG Oncology
Glioblastoma, Gliosarcoma, Supratentorial Glioblastoma
03/13
03/13
NCT01480479 / 2011-006068-32: Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma

Checkmark First Interim data from ACT IV trial in frontline GBM [Trial failed]
May 2016 - May 2016: First Interim data from ACT IV trial in frontline GBM [Trial failed]
Checkmark Second interim analysis of P3 ACT IV trial in front-line GBM [Trial failed]
May 2016 - May 2016: Second interim analysis of P3 ACT IV trial in front-line GBM [Trial failed]
Checkmark From ACT IV trial for front-line GBM at SNO 2016 [Trial failed]
More
Completed
3
745
US, Canada, Europe, RoW
Rindopepimut (CDX-110) with GM-CSF, CDX-110 with sargramostim (GM-CSF) (Leukine®), Temozolomide, Temodar, Temodal, KLH
Celldex Therapeutics
Glioblastoma, Small Cell Glioblastoma, Giant Cell Glioblastoma, Gliosarcoma, Glioblastoma With Oligodendroglial Component
11/16
11/16
NCT03495921: A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide

Terminated
3
32
US
Vigil, Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy, FANG vaccine, Irinotecan, Camptosar, Camptothecin-11, CPT-11, Temozolomide, Temodar
Gradalis, Inc.
Ewing Sarcoma, Ewing Family of Tumors, Ewing's Tumor Metastatic, Ewing's Sarcoma Metastatic, Ewing's Tumor Recurrent, Rare Diseases, Sarcoma, Neoplasms, Connective and Soft Tissue, Neoplasms by Histologic Type, Neoplasms, Bone Tissue, Neoplasms, Connective Tissue, Sarcoma, Ewing, Neoplasms
01/22
01/22
Intellance1, NCT02573324 / 2015-001166-26: A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification

Checkmark From Intellance-1 trial in 1L GBM
May 2019 - May 2019: From Intellance-1 trial in 1L GBM
Completed
3
691
Europe, Canada, US, RoW
Temozolomide, Depatuxizumab mafodotin, ABT-414, Radiation, Placebo for ABT-414
AbbVie, Radiation Therapy Oncology Group
Glioblastoma, Gliosarcoma
04/22
04/22
NRG-BN011, NCT05095376: Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine®) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma

Recruiting
3
306
US
Lomustine, 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea, 1-Nitrosourea, 1-(2-chloroethyl)-3-cyclohexyl-, Belustin, Belustine, CCNU, Cecenu, CeeNU, Chloroethylcyclohexylnitrosourea, Citostal, Gleostine, Lomeblastin, Lomustinum, Lucostin, Lucostine, N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea, Prava, RB-1509, WR-139017, Photon Beam Radiation Therapy, Photon EBRT, Photon External Beam Radiotherapy, Radiation, Photon Beam, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac, TMZ
NRG Oncology, National Cancer Institute (NCI)
Glioblastoma, Gliosarcoma
08/26
08/31
2014-000259-99: A comparison of four widely used chemotherapy regimens for the treatment of Ewing sarcoma, a type of bone cancer, to see which is most effective and/or has the fewest side effects.

Ongoing
2/3
400
Europe
Cyclophosphamide, Topotecan, Irinotecan, Temozolomide, Gemcitabine, Docetaxel, Ifosfamide, Cyclophosphamide, Topotecan, Irinotecan, Temozolomide, Gemcitabine, Docetaxel, Ifosfamide, Infusion, Capsule, hard, , Cyclophosphamide, HYCAMTIN, CAMPTO, Temodal, GEMZAR, TAXOTERE, Ifosfamide
University of Birmingham, UNIVERSITY OF BIRMINGHAM, European Commission, German Cancer Aid
Recurrent and refractory Ewing sarcoma, Ewing sarcoma, a type of bone cancer, that has either grown during initial treatment or has grown after the end of treatment., Diseases [C] - Cancer [C04]
 
 
A071102, NCT02152982: Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Active, not recruiting
2/3
447
US
Laboratory Biomarker Analysis, Placebo Administration, Quality-of-Life Assessment, Quality of Life Assessment, Temozolomide, CCRG-81045, Gliotem, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temizole, Temodal, Temodar, Temomedac, TMZ, Veliparib, ABT 888, ABT-888, ABT888, PARP-1 inhibitor ABT-888
National Cancer Institute (NCI)
Glioblastoma, Gliosarcoma
12/21
12/24
NRG-BN007, NCT04396860: Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

Active, not recruiting
2/3
159
US
Contrast-enhanced Magnetic Resonance Imaging, CONTRAST ENHANCED MRI, Contrast-enhanced MRI, MRI With Contrast, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS 734016, BMS-734016, BMS734016, Ipilimumab Biosimilar CS1002, MDX 010, MDX-010, MDX-CTLA4, MDX010, Yervoy, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, NovoTTF-100A Device, NovoTTF-100A, NovoTTF-100A System, NovoTTF-100A system (Optune), NovoTTFields, NovoTumor Treatment Fields, Optune, Optune Device, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Temozolomide, CCRG-81045, Gliotem, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temizole, Temodal, Temodar, Temomedac, TMZ
National Cancer Institute (NCI), NRG Oncology
Gliosarcoma, MGMT-Unmethylated Glioblastoma
04/23
03/25
A092104, NCT05633381: Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working

Recruiting
2/3
70
US
Olaparib, 763113-22-0, Temozolomide, 85622-93-1, Trabectedin, 114899-77-3, Pazopanib, 444731-52-6, 790713-33-6
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Locally Advanced Leiomyosarcoma, Metastatic Leiomyosarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8, Unresectable Leiomyosarcoma, Uterine Corpus Leiomyosarcoma
03/30
03/30
NCT05432791: Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working

Suspended
2/3
190
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Olaparib, AZD 2281, AZD-2281, AZD2281, KU 0059436, KU-0059436, KU0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281, Pazopanib, GW786034, Temozolomide, CCRG-81045, Gliotem, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temizole, Temodal, Temodar, Temomedac, TMZ, Trabectedin, Ecteinascidin, Ecteinascidin 743, ET 743, ET-743, ET743, Yondelis, Transthoracic Echocardiography, TTE
National Cancer Institute (NCI)
Locally Advanced Uterine Corpus Leiomyosarcoma, Metastatic Uterine Corpus Leiomyosarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8, Unresectable Uterine Corpus Leiomyosarcoma
03/30
03/30

Download Options